PTW-002 Gel for Epidermolysis Bullosa
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new treatment called PTW-002 for patients with a rare skin condition caused by a genetic mutation. The treatment aims to strengthen their skin and reduce blistering.
Will I have to stop taking my current medications?
The trial requires that you stop using aminoglycosides (a type of antibiotic) at least 7 days or 5 half-lives before the study starts, except for eye drops. If you're using any investigational drugs or devices, you must stop them 28 days or 5 half-lives before the study begins.
What safety data exists for PTW-002 Gel or similar treatments for skin conditions?
How does PTW-002 Gel differ from other treatments for epidermolysis bullosa?
Who Is on the Research Team?
Hal Landy, MD
Principal Investigator
Phoenicis Therapeutics
Are You a Good Fit for This Trial?
This trial is for children and adults with Dystrophic Epidermolysis Bullosa (DEB) due to specific gene mutations. Participants must have a caregiver, no signs of local infection in the target wound area, and agree to use contraception if applicable. Excluded are those with certain treatments or conditions that could affect safety or study results.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple doses of PTW-002 or placebo to evaluate safety, proof of mechanism, preliminary efficacy, and systemic exposure
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PTW-002
Find a Clinic Near You
Who Is Running the Clinical Trial?
Phoenicis Therapeutics
Lead Sponsor